Harvey M Friedman Selected Research

Herpes Genitalis (Genital Herpes)

1/2022	Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine.
1/2022	An mRNA vaccine to prevent genital herpes.
12/2021	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models.
12/2021	Guinea Pig and Mouse Models for Genital Herpes Infection.
11/2020	Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.
1/2020	Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.
1/2020	An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.
1/2020	Vaccines to prevent genital herpes.
1/2019	A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.
1/2019	Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harvey M Friedman Research Topics

Disease

29	Infections 01/2022 - 12/2003
20	Herpes Genitalis (Genital Herpes) 01/2022 - 10/2011
5	Genital Diseases 01/2020 - 02/2014
4	Neonatal herpes 11/2020 - 01/2017
4	Reinfection 12/2017 - 04/2011
2	COVID-19 01/2022 - 12/2021
2	Asymptomatic Infections 01/2020 - 01/2019
2	Latent Infection 01/2020 - 08/2015
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/2012 - 11/2011
1	Herpes Zoster 12/2017
1	Pain (Aches) 01/2017
1	Vaginal Diseases 04/2012
1	Herpes Simplex 01/2006
1	Ganglion Cysts (Ganglion) 11/2005

Drug/Important Bio-Agent (IBA)

23	VaccinesIBA 01/2022 - 01/2006
14	Glycoproteins (Glycoprotein)IBA 11/2020 - 10/2004
7	AntibodiesIBA 01/2022 - 12/2003
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2008
7	AntigensIBA 11/2020 - 02/2014
6	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 04/2012
5	Messenger RNA (mRNA)IBA 01/2022 - 01/2019
5	NucleosidesIBA 01/2022 - 01/2019
4	mRNA VaccinesIBA 01/2022 - 01/2020
3	Neutralizing AntibodiesIBA 01/2022 - 01/2018
3	Immunoglobulin G (IgG)IBA 04/2011 - 09/2005
2	EpitopesIBA 01/2022 - 01/2018
2	Lipid NanoparticlesIBA 01/2022 - 11/2020
2	Subunit VaccinesIBA 01/2020 - 08/2014
2	Monoclonal AntibodiesIBA 01/2018 - 12/2003
2	herpes simplex virus type 1 glycoprotein gCIBA 08/2015 - 02/2014
2	GC 1 compoundIBA 11/2009 - 09/2005
1	glycoprotein D-herpes simplex virus type 2IBA 01/2022
1	Indicators and Reagents (Reagents)IBA 12/2021
1	CytokinesIBA 12/2021
1	aluminum sulfate (alum)IBA 11/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Imiquimod (Aldara)FDA LinkGeneric 01/2019
1	Capsid Proteins (Capsid Protein)IBA 08/2015
1	Acetic Acid (Vinegar)FDA LinkGeneric 03/2012
1	Viral ProteinsIBA 09/2010
1	Retinaldehyde (Retinal)IBA 09/2009
1	Lactose FDA LinkGeneric 01/2009
1	CarbohydratesIBA 01/2009
1	Galectin 3 (LGALS3)IBA 01/2009
1	NectinsIBA 02/2008
1	Keratins (Keratin)IBA 01/2006
1	Viral AntigensIBA 11/2005
1	Blocking AntibodiesIBA 09/2005
1	Small Interfering RNA (siRNA)IBA 10/2004

Therapy/Procedure

1	Euthanasia (Mercy Killing) 12/2021
1	Punctures 12/2021
1	Therapeutics 01/2020
1	Immunotherapy 12/2017